These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. CT monitoring of chemotherapeutic agent delivery after osmotic blood brain barrier disruption. Neuwelt EA Clin Neurosurg; 1981; 28():520-31. PubMed ID: 6895614 [No Abstract] [Full Text] [Related]
8. Physicochemical considerations and pharmacokinetic behavior in delivery of drugs to the central nervous system. Mellett LB Cancer Treat Rep; 1977 Jul; 61(4):527-31. PubMed ID: 884690 [TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and the blood-brain barrier. Blasberg RG Natl Cancer Inst Monogr; 1977 Dec; 46():19-27. PubMed ID: 349396 [No Abstract] [Full Text] [Related]
10. Blood-brain barrier and drug delivery in central nervous system tumors. Watts C Ann Neurol; 1987 Jun; 21(6):614-5. PubMed ID: 3606050 [No Abstract] [Full Text] [Related]
11. Innovations in design and delivery of chemotherapy for brain tumors. Gururangan S; Friedman HS Neuroimaging Clin N Am; 2002 Nov; 12(4):583-97. PubMed ID: 12687913 [TBL] [Abstract][Full Text] [Related]
12. Targeted therapy and blood-brain barrier. Korfel A; Thiel E Recent Results Cancer Res; 2007; 176():123-33. PubMed ID: 17607920 [TBL] [Abstract][Full Text] [Related]
13. Forbeck forum on improved drug delivery to brain tumors. Freeman AI; Fenstermacher J; Shapiro W; Kemshead J; Chasin M; Colvin OM; Diksic M; Finley J; Hertler A; Levin V Sel Cancer Ther; 1990; 6(3):109-18. PubMed ID: 1980750 [No Abstract] [Full Text] [Related]
14. Noninvasive nanoparticle strategies for brain tumor targeting. Sun C; Ding Y; Zhou L; Shi D; Sun L; Webster TJ; Shen Y Nanomedicine; 2017 Nov; 13(8):2605-2621. PubMed ID: 28756093 [TBL] [Abstract][Full Text] [Related]
15. Chemotherapy of brain tumors: physiological and pharmacokinetic considerations. Blasberg RG; Groothuis DR Semin Oncol; 1986 Mar; 13(1):70-82. PubMed ID: 3513317 [No Abstract] [Full Text] [Related]
16. [New methods of drug delivery through the blood brain barrier]. Bruhn C Dtsch Med Wochenschr; 2012 May; 137(21):p18. PubMed ID: 22622506 [No Abstract] [Full Text] [Related]
17. Brain tumors: controversies and challenges in management. Lesniak MS Expert Rev Neurother; 2005 Nov; 5(6 Suppl):1-2. PubMed ID: 16274264 [No Abstract] [Full Text] [Related]
18. Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium. Doolittle ND; Abrey LE; Ferrari N; Hall WA; Laws ER; McLendon RE; Muldoon LL; Peereboom D; Peterson DR; Reynolds CP; Senter P; Neuwelt EA Clin Cancer Res; 2002 Jun; 8(6):1702-9. PubMed ID: 12060607 [TBL] [Abstract][Full Text] [Related]
19. The role of positron emission tomography in the study of cerebral tumors. Brooks DJ; Beaney RP; Thomas DG Semin Oncol; 1986 Mar; 13(1):83-93. PubMed ID: 3006259 [No Abstract] [Full Text] [Related]
20. Evaluation of permeability, doxorubicin delivery, and drug retention in a rat brain tumor model after ultrasound-induced blood-tumor barrier disruption. Park J; Aryal M; Vykhodtseva N; Zhang YZ; McDannold N J Control Release; 2017 Mar; 250():77-85. PubMed ID: 27742444 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]